Vaxart (VXRT) Corporate presentation summary

Transformative oral vaccine platform

• Oral pill vaccine platform generates both systemic and mucosal immunity, offering broader protection and easier distribution due to its thermostable format.

• Platform validated by encouraging safety data from COVID-19 sentinel cohort and efficacy demonstrated in COVID-19, norovirus, and influenza indications.

• Manufacturing is fully based in the United States, supporting supply chain reliability.

Clinical pipeline and efficacy

• COVID-19 oral vaccine in Phase 2b head-to-head trial with ~5,400 subjects, comparing safety and efficacy to an approved mRNA vaccine; main cohort data expected H1/2027.

• Norovirus program shows significant reduction in infection and viral shedding in Phase 2 challenge; second-generation candidate demonstrates enhanced antibody responses.

• Influenza oral vaccine demonstrated at least comparable protection to leading injectable vaccine in Phase 2 challenge, with reduced viral shedding and favorable safety.

• Avian flu (H5N1) oral vaccine showed 100% survival in animal challenge model.

Safety and tolerability

• Oral pill vaccine showed lower systemic and local adverse events compared to mRNA comparator in COVID-19 trial; no vaccine-related serious adverse events or sustained severe events observed.

• Safety profile consistent across studies, with over 3,880 subjects dosed to date.